Documenta Ophthalmologica

, 119:217 | Cite as

Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST)

  • M. Klein
  • D. G. Birch
Original research article


To determine whether the Diagnosys full-field stimulus threshold (D-FST) is a valid, sensitive and repeatable psychophysical method of measuring and following visual function in low-vision subjects. Fifty-three affected eyes of 42 subjects with severe retinal degenerative diseases (RDDs) were tested with achromatic stimuli on the D-FST. Included were subjects who were either unable to perform a static perimetric field or had non-detectable or sub-microvolt electroretinograms (ERGs). A subset of 21 eyes of 17 subjects was tested on both the D-FST and the FST2, a previous established full-field threshold test. Seven eyes of 7 normal control subjects were tested on both the D-FST and the FST2. Results for the two methods were compared with the Bland–Altman test. On the D-FST, a threshold could successfully be determined for 13 of 14 eyes with light perception (LP) only (median 0.9 ± 1.4 log cd/m2), and all eyes determined to be counting fingers (CF; median 0.3 ± 1.8 log cd/m2). The median full-field threshold for the normal controls was −4.3 ± 0.6 log cd/m2 on the D-FST and −4.8 ± 0.9 log cd/m2 on the FST2. The D-FST offers a commercially available method with a robust psychophysical algorithm and is a useful tool for following visual function in low vision subjects.


Psychophysics Treatment trials Retina LCA RP CRD 



We would like to thank Hemaxi Patel for her help with testing and both the patients with retinal degenerative diseases and normal subjects for participating in this study. This study was supported by funds from the Foundation Fighting Blindness.


  1. 1.
    Inoue Y, Iriyama A, Ueno S, Takahashi H, Kondo M, Tamaki Y, Araie M, Yanagi Y (2007) Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration. Exp Eye Res 85(2):234–241CrossRefPubMedGoogle Scholar
  2. 2.
    Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358(21):2240–2248CrossRefPubMedGoogle Scholar
  3. 3.
    Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28(1):92–95CrossRefPubMedGoogle Scholar
  4. 4.
    Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358(21):2231–2239CrossRefPubMedGoogle Scholar
  5. 5.
    Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19(10):979–990CrossRefPubMedGoogle Scholar
  6. 6.
    Rizzo JF 3rd, Wyatt J, Loewenstein J, Kelly S, Shire D (2003) Methods and perceptual thresholds for short-term electrical stimulation of human retina with microelectrode arrays. Invest Ophthalmol Vis Sci 44(12):5355–5361CrossRefPubMedGoogle Scholar
  7. 7.
    Caspi A, Dorn JD, McClure KH, Humayun MS, Greenberg RJ, McMahon MJ (2009) Feasibility study of a retinal prosthesis: spatial vision with a 16-electrode implant. Arch Ophthalmol 127(4):398–401CrossRefPubMedGoogle Scholar
  8. 8.
    Roman AJ, Schwartz SB, Aleman TS, Cideciyan AV, Chico JD, Windsor EA, Gardner LM, Ying GS, Smilko EE, Maguire MG, Jacobson SG (2005) Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res 80(2):259–272CrossRefPubMedGoogle Scholar
  9. 9.
    Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG (2007) Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas 28(8):N51–N56CrossRefPubMedGoogle Scholar
  10. 10.
    Swanson WH, Birch EE (1992) Extracting thresholds from noisy psychophysical data. Percept Psychophys 51(5):409–422PubMedGoogle Scholar
  11. 11.
    Bloch AM (1885) Experiences sur la vision. CRSM Soc Biol 8/TII 28:493–495Google Scholar
  12. 12.
    Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307–310PubMedGoogle Scholar
  13. 13.
    Peters AYL, Locke KG, Birch DG (2000) Comparison of the Goldmann–Weekers dark adaptometer and LKC Technologies Scotopic Sensitivity tester-1. Doc Ophthalmol 101(1):1–9CrossRefPubMedGoogle Scholar
  14. 14.
    Barlow HB (1958) Temporal and spatial summation in human vision at different background intensities. J Physiol 141(2):337–350PubMedGoogle Scholar
  15. 15.
    Jacobson SG, Aleman TS, Cideciyan AV, Roman AJ, Sumaroka A, Windsor EAM, Schwartz SB, Heon E, Stone E (2009) Defining the residual vision in Leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 50:2368–2375CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Retina Foundation of the SouthwestDallasUSA
  2. 2.Department of OphthalmologyUT Southwestern Medical CenterDallasUSA

Personalised recommendations